Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 148

1.

Effectiveness of omalizumab in non-allergic severe asthma.

Domingo C, Pomares X, Angril N, Rudi N, Amengual MJ, Mirapeix RM.

J Biol Regul Homeost Agents. 2013 Jan-Mar;27(1):45-53.

PMID:
23489686
[PubMed - indexed for MEDLINE]
2.

Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma.

Pelaia G, Gallelli L, Romeo P, Renda T, Busceti MT, Proietto A, Grembiale RD, Marsico SA, Maselli R, Vatrella A.

Int J Clin Pharmacol Ther. 2011 Dec;49(12):713-21.

PMID:
22122813
[PubMed - indexed for MEDLINE]
3.

Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.

Tzortzaki EG, Georgiou A, Kampas D, Lemessios M, Markatos M, Adamidi T, Samara K, Skoula G, Damianaki A, Schiza S, Tzanakis N, Siafakas NM.

Pulm Pharmacol Ther. 2012 Feb;25(1):77-82. doi: 10.1016/j.pupt.2011.11.004. Epub 2011 Dec 3.

PMID:
22155001
[PubMed - indexed for MEDLINE]
4.

Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.

Siergiejko Z, Świebocka E, Smith N, Peckitt C, Leo J, Peachey G, Maykut R.

Curr Med Res Opin. 2011 Nov;27(11):2223-8. doi: 10.1185/03007995.2011.620950. Epub 2011 Sep 21.

PMID:
21933100
[PubMed - indexed for MEDLINE]
5.

Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).

Rubin AS, Souza-Machado A, Andradre-Lima M, Ferreira F, Honda A, Matozo TM; QUALITX Study Investigators.

J Asthma. 2012 Apr;49(3):288-93. doi: 10.3109/02770903.2012.660297. Epub 2012 Feb 23.

PMID:
22356355
[PubMed - indexed for MEDLINE]
6.

Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study.

Maselli DJ, Singh H, Diaz J, Peters JI.

Ann Allergy Asthma Immunol. 2013 Jun;110(6):457-61. doi: 10.1016/j.anai.2013.04.011.

PMID:
23706716
[PubMed - indexed for MEDLINE]
7.

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, Taylor AF, Rohane P.

Pediatrics. 2001 Aug;108(2):E36.

PMID:
11483846
[PubMed - indexed for MEDLINE]
8.

[Retrospective analysis of omalizumab in patients with severe allergic asthma].

Padullés Zamora N, Comas Sugrañes D, Méndez Cabaleiro N, Figueras Suriol A, Jodar Masanes R.

Farm Hosp. 2013 Sep-Oct;37(5):399-405. doi: 10.7399/FH.2013.37.5.728. Spanish.

PMID:
24128103
[PubMed - indexed for MEDLINE]
Free Article
9.

Omalizumab therapy in severe asthma: experience from the Spanish registry--some new approaches.

Vennera Mdel C, Pérez De Llano L, Bardagí S, Ausin P, Sanjuas C, González H, Gullón JA, Martínez-Moragón E, Carretero JA, Vera E, Medina JF, Alvarez FJ, Entrenas LM, Padilla A, Irigaray R, Picado C; Spanish Registry.

J Asthma. 2012 May;49(4):416-22. doi: 10.3109/02770903.2012.668255. Epub 2012 Mar 23.

PMID:
22443408
[PubMed - indexed for MEDLINE]
10.

Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy.

Zhu R, Zheng Y, Putnam WS, Visich J, Eisner MD, Matthews JG, Rosen KE, D'Argenio DZ.

AAPS J. 2013 Apr;15(2):559-70. doi: 10.1208/s12248-013-9463-9. Epub 2013 Feb 15.

PMID:
23413101
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.

Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Lenczewska D, Bodzenta-Lukaszyk A.

Int Arch Allergy Immunol. 2011;154(1):25-32. doi: 10.1159/000319205. Epub 2010 Jul 24.

PMID:
20664274
[PubMed - indexed for MEDLINE]
12.

Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.

Chipps BE, Figliomeni M, Spector S.

Allergy Asthma Proc. 2012 Sep-Oct;33(5):377-85. doi: 10.2500/aap.2012.33.3599.

PMID:
23026179
[PubMed - indexed for MEDLINE]
13.

Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.

Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H.

Allergy. 2004 Jul;59(7):701-8.

PMID:
15180756
[PubMed - indexed for MEDLINE]
14.

Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.

Özgür ES, Özge C, Ïlvan A, Naycı SA.

J Asthma. 2013 Aug;50(6):687-94. doi: 10.3109/02770903.2013.792348. Epub 2013 May 9.

PMID:
23557459
[PubMed - indexed for MEDLINE]
15.

Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.

Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM, Busse W.

Am J Respir Crit Care Med. 2013 Apr 15;187(8):804-11. doi: 10.1164/rccm.201208-1414OC.

PMID:
23471469
[PubMed - indexed for MEDLINE]
16.

A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma.

Garcia G, Magnan A, Chiron R, Contin-Bordes C, Berger P, Taillé C, Devouassoux G, de Blay F, Couderc LJ, Didier A, O'Callaghan DS, Girodet PO, Bourdeix I, Le Gros V, Humbert M.

Chest. 2013 Aug;144(2):411-9. doi: 10.1378/chest.12-1961.

PMID:
23579324
[PubMed - indexed for MEDLINE]
17.

Total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations in patients with severe persistent allergic asthma: its relation to omalizumab treatment.

Yalcin AD, Gorczynski RM, Parlak GE, Kargi A, Bisgin A, Sahin E, Kose S, Gumuslu S.

Clin Lab. 2012;58(1-2):89-96.

PMID:
22372350
[PubMed - indexed for MEDLINE]
18.

Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab.

Chen H, Eisner MD, Haselkorn T, Trzaskoma B.

Respir Med. 2013 Jan;107(1):60-7. doi: 10.1016/j.rmed.2012.09.008. Epub 2012 Oct 18.

PMID:
23083840
[PubMed - indexed for MEDLINE]
19.

The oral corticosteroid-sparing effect of omalizumab in children with severe asthma.

Brodlie M, McKean MC, Moss S, Spencer DA.

Arch Dis Child. 2012 Jul;97(7):604-9. doi: 10.1136/archdischild-2011-301570. Epub 2012 Jun 9.

PMID:
22685051
[PubMed - indexed for MEDLINE]
20.

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.

Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, Woolacott N.

Pharmacoeconomics. 2012 Nov 1;30(11):991-1004. doi: 10.2165/11597160-000000000-00000. Review.

PMID:
22950547
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk